Enzyme by Design

Executive Summary

Enzyme by Design is a private biotechnology company headquartered in Cambridge, MA, with a secondary presence in Chicago. Founded in 2018, the company is dedicated to engineering safer cancer therapeutics by redesigning enzymes to mitigate dangerous side effects and improve patient quality of life. Its initial focus is on optimizing L-asparaginase, a cornerstone therapy for acute lymphoblastic leukemia (ALL). Current L-asparaginase formulations are associated with significant toxicity, including hypersensitivity, pancreatitis, and thrombosis, which can limit their use and compromise treatment outcomes. Enzyme by Design leverages computational protein design and directed evolution to create enzyme variants with enhanced stability, reduced immunogenicity, and improved pharmacokinetic profiles. By addressing these limitations, the company aims to expand the therapeutic index of L-asparaginase and potentially enable its use in additional indications. Although still in early stages, Enzyme by Design's approach could address a clear unmet need in ALL therapy, where safer and more tolerable enzyme-based treatments are highly desired.

Upcoming Catalysts (preview)

• TBDPublication of preclinical proof-of-concept data60% success
• Q4 2026Series A financing round50% success
• H1 2027In-licensing or partnership with a larger biopharma for ALL L-asparaginase30% success